BioMarin focuses on developing treatments for rare diseases. It’s expected to report third quarter results this week.
Goldman says that the company has room for growth with its recently launched Palynziq, which treats adult phenylketonuria, a rare inherited disorder in which the body can’t process an amino acid called phenylalanine
Goldman also said treatments with potential include vosoritide (treats achondroplasia, a type of short-limbed dwarfism), val-rox (hemophilia A gene therapy), and BMN250 (treats Sanfilippo Syndrome B).
Source: Business Insider
To Read Our Daily News Updates, Please visit Inventiva or Subscribe Our Newsletter & Push.
Here are the biotech stocks investors should own now, according to Goldman Sachs
